Skip to main content

favezelimab

Generic: Favezelimab

favezelimab: 3 clinical trials tracked.

favezelimab evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about favezelimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

NCT03598608Registry updated 2026-07-28·Phase 1/Phase 2
Terminated

Primary endpoint: Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)

Interventionalopen137 enrolledStarted 2018-10Completion 2026-0125 sites · Australia, Canada, Germany, Israel…Merck Sharp & Dohme LLC

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

NCT03486873Registry updated 2026-09-10·Phase 3
Recruiting

Primary endpoint: Overall Survival (OS)

Interventionalopen3,500 targetStarted 2018-08Completion 2043-0850 sites · United StatesMerck Sharp & Dohme LLC

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors

NCT02720068Registry updated 2025-05-30·Phase 1
Completed

Primary endpoint: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)

Interventionalopen481 enrolledStarted 2016-05Completion 2024-03Merck Sharp & Dohme LLC